Applied DNA and EvviVax Announce Peer-Reviewed Publication of Positive Preclinical Data for LinearDNA™ Platform as a Novel Cancer Vaccine Strategy in the Journal of Experimental & Clinical Cancer Research

Applied DNA and EvviVax Announce Peer-Reviewed Publication of Positive Preclinical Data for LinearDNA™ Platform as a Novel Cancer Vaccine Strategy in the Journal of Experimental & Clinical Cancer Research
CANNANNEW REPORT

– Data Supports Initiation of First Canine Clinical Trial by Applied DNA to Advance Canine Lymphoma Cancer Vaccine Licensed from EvviVax –     STONY BROOK, N.Y. and ROME, Italy–(BUSINESS WIRE)–$APDN #LinearDNA—Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in cell-free, enzymatic DNA production, and its program development partner, EvviVax, S.R.L. (“EvviVax”), today announced the peer-reviewed publication of preclinical animal data in The Journal of Experimental & Clinical Cancer Research that supports the use of Applied DNA’s LinearDNA™ platform to produce veterinary DNA cancer vaccines. LinearDNA is Applied DNA’s proprietary, large-scale polymerase chain reaction (PCR)-based manufacturing platform that allows for the large-scale, cell-free production of high-fidelity DNA sequences. The paper, titled “Linear DNA Amplicons as a Novel Cancer Vaccine Strategy” and previously published on the non-refereed, open-access preprint archive bioRxiv in February 2022, investigated two LinearDNA therapeutic cancer vaccines that were found to produce a strong immune and specific antitumoral response in mouse models using electro-gene-transfer (EGT) as the delivery method. Applied DNA has exclusively licensed the anti-telomerase reverse transcriptase (TERT) cancer vaccine studied in the paper for its LinearDNA platform for veterinary applications. Based on the positive data from the paper, Applied DNA intends to initiate an initial clinical trial for canine B-cell lymphoma in the current calendar year to validate the TERT cancer vaccine in conjunction with a lipid nanoparticle-based (LNP) delivery system. Dr. Luigi Aurisicchio, CEO and chief scientific officer of Evvivax S.R.L., commented, “Prior clinical trials conducted by EvviVax using a plasmid DNA and adenovirus vector form of the TERT vaccine together with the standard of care chemotherapy showed an increase in the survival of canines with Stage III/IV B cell lymphoma by almost three-fold, from 37 weeks to 97 weeks. While clinically successful, our regulatory review was not extended due to hurdles related to…

Excerpt only …
READ MORE BELOW
Source : Applied DNA and EvviVax Announce Peer-Reviewed Publication of Positive Preclinical Data for LinearDNA™ Platform as a Novel Cancer Vaccine Strategy in the Journal of Experimental & Clinical Cancer Research

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.